Kaye, Stan B.Lubinski, JanGourley, CharlieLowe, Elizabeth S.Kaufman, Bella2025-01-132025-01-132011-12-27Kaye, S. B., Lubinski, J., Matulonis, U., Ang, J. E., Gourley, C., Karlan, B. Y., ... & Kaufman, B. (2012). Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. Journal of clinical oncology, 30(4), 372-379.https://doi.org/10.1200/JCO.2011.36.9215https://nru.uncst.go.ug/handle/123456789/9755Olaparib (AZD2281), an orally active poly (ADP-ribose) polymerase inhibitor that induces synthetic lethality in BRCA1- or BRCA2-deficient cells, has shown promising clinical efficacy in nonrandomized phase II trials in patients with ovarian cancer with BRCA1 or BRCA2 deficiency. We assessed the comparative efficacy and safety of olaparib and pegylated liposomal doxorubicin (PLD) in this patient population.enArticle